UCB boards T cell engager train in $60M upfront deal with Antengene
UCB boards T cell engager train in $60M upfront deal with Antengene
Body unavailable. Use the original source.
UCB boards T cell engager train in $60M upfront deal with Antengene
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.